Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-a... read more

Compact POCT Platform Unlocks Multiplexing Potential of Real-Time PCR

By LabMedica International staff writers
Posted on 24 Feb 2023

Image: New real-time PCR platform will detect infectious diseases in POC settings (Photo courtesy of Co-Diagnostics)

A new real-time PCR platform aims to disrupt the molecular diagnostics status quo by bringing revolutionary lab-grade PCR testing capabilities - the gold standard in infectious disease testing -into homes and businesses. Developed by world-renowned scientists and designed to give users the power to know, the platform will use disposable cartridges and smartphone connectivity to offer gold standard PCR testing at home, the office, and at school without the need for a lab.

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has commenced clinical evaluations for its at-home and point-of-care Co-Dx PCR Home platform and initial COVID-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the US FDA and other regulatory bodies. The company has developed the real-time PCR platform for the detection of infectious diseases in at-home and point-of-care settings. Co-Diagnostics plans to come out with multiplex panels after receiving the initial regulatory authorization for the platform.

"The commencement of our clinical evaluations represents the achievement of a profound milestone for our company. It is the culmination of a development process that spans over two years of research and development and has harnessed the expert skills of well over a hundred dedicated scientists, engineers, and support staff. The new at-home and point-of-care testing (POCT) platform represents a high degree of innovation that brings together the power of our patented Co-Primer™ technology coupled with other proprietary IP, setting a new standard for compact POCT that unlocks the multiplexing potential of real-time PCR," said Dwight Egan, CEO of Co-Diagnostics. "We believe this invention holds significant promise for the United States and around the world, including regions of the globe that have not previously had access to the quality-of-life advantages of inexpensive, powerful, accurate diagnostic technology. We are excited to begin these clinical evaluations and to leverage the power of our groundbreaking science in this new and revolutionary platform."

Related Links:
Co-Diagnostics, Inc.